Article
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
The Lancet. Haematology - 1 Mar 2018
Jerkeman Mats, Eskelund Christian Winther, Hutchings Martin, Räty Riikka, Wader Karin Fahl, Laurell Anna, Toldbod Helle, Pedersen Lone Bredo, Niemann Carsten Utoft, Dahl Christina, Kuitunen Hanne, Geisler Christian H, Grønbæk Kirsten, Kolstad Arne
Abstract excerpt
BACKGROUND: Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previously published data on either regimen alone. METHODS: In this multicentre, open-label, single-arm, phase 2 trial, we enrolled patients aged 18...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.